{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:23:59Z","timestamp":1725150239415},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"DOI":"10.7759\/cureus.68260","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T06:58:16Z","timestamp":1725087496000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Antipsychotic-Induced Neuroleptic Malignant Syndrome Using a Self-Organizing Map"],"prefix":"10.7759","author":[{"given":"Koumi","family":"Miyasaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakiko","family":"Hirofuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanaka","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Nokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Ministry of Health, Labour and Welfare. The manual for handling disorders due to adverse drug reactions. neuroleptic malignant syndrome. (2008). Accessed: June 26, 2024: https:\/\/www.pmda.go.jp\/files\/000144356.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redare.2022.06.004","article-title":"Neuroleptic malignant syndrome in a postoperative patient: a case report","volume":"69","author":"Fervienza A","year":"2022","unstructured":"Fervienza A, L\u00f3pez-Baamonde M, Jacas A, Mu\u00f1oz G, Ib\u00e1\u00f1ez C, Del Rio ME. Neuroleptic malignant syndrome in a postoperative patient: a case report. Rev Esp Anestesiol Reanim (Engl Ed). 2022, 69:364-7. 10.1016\/j.redare.2022.06.004","journal-title":"Rev Esp Anestesiol Reanim (Engl Ed)"},{"key":"ref3","article-title":"Neuroleptic malignant syndrome","author":"Simon LV","year":"2023","unstructured":"Simon LV, Hashmi MF, Callahan AL. Neuroleptic malignant syndrome. StatPearls (Internet). StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2174\/1570159x13999150424113345","article-title":"Neuroleptic malignant syndrome: a review from a clinically oriented perspective","volume":"13","author":"Tse L","year":"2015","unstructured":"Tse L, Barr AM, Scarapicchia V, Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015, 13:395-406. 10.2174\/1570159x13999150424113345","journal-title":"Curr Neuropharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson JL","year":"1985","unstructured":"Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985, 142:1137-45. 10.1176\/ajp.142.10.1137","journal-title":"Am J Psychiatry"},{"key":"ref6","article-title":"Epidemiology of neuroleptic malignant syndrome","volume":"22","author":"Adityanjee","year":"1999","unstructured":"Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol. 1999, 22:151-8.","journal-title":"Clin Neuropharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21891","article-title":"Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system","volume":"9","author":"Hirofuji S","year":"2023","unstructured":"Hirofuji S, Miyasaka K, Maezawa M, et al.. Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system. Heliyon. 2023, 9:e21891. 10.1016\/j.heliyon.2023.e21891","journal-title":"Heliyon"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/9780470977811","article-title":"Cluster Analysis, 5th ed","author":"Everitt BS","year":"2011","unstructured":"Everitt BS, Landau S, Leese M, Stahl D. Cluster Analysis, 5th ed. John Wiley & Sons, Ltd, New York; 2011. 10.1002\/9780470977811"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12647","article-title":"Statistical significance for hierarchical clustering","volume":"73","author":"Kimes PK","year":"2017","unstructured":"Kimes PK, Liu Y, Neil Hayes D, Marron JS. Statistical significance for hierarchical clustering. Biometrics. 2017, 73:811-21. 10.1111\/biom.12647","journal-title":"Biometrics"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-00784-6","article-title":"Self-Organization and Associative Memory, 2nd ed. Springer Series in Information Sciences","author":"Kohonen T","year":"1988","unstructured":"Kohonen T. Self-Organization and Associative Memory, 2nd ed. Springer Series in Information Sciences. Springer-Verlag, Berlin; 1988. 10.1007\/978-3-662-00784-6"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2011.08.002","article-title":"In silico prediction of rhabdomyolysis of compounds by self-organizing map and support vector machine","volume":"25","author":"Hu X","year":"2011","unstructured":"Hu X, Yan A. In silico prediction of rhabdomyolysis of compounds by self-organizing map and support vector machine. Toxicol In Vitro. 2011, 25:2017-24. 10.1016\/j.tiv.2011.08.002","journal-title":"Toxicol In Vitro"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.14-00145","article-title":"Visualization and analysis of adverse reactions of molecularly targeted anticancer agents using the self-organizing map (SOM)","volume":"134","author":"Hamamoto T","year":"2014","unstructured":"Hamamoto T, Serizawa A, Ohtsuki K, Kawakami J, Sato K. Visualization and analysis of adverse reactions of molecularly targeted anticancer agents using the self-organizing map (SOM). Yakugaku Zasshi. 2014, 134:1069-80. 10.1248\/yakushi.14-00145","journal-title":"Yakugaku Zasshi"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.13-00201","article-title":"Visualization and analysis of drug information on adverse reactions using data mining method, and its clinical application","volume":"134","author":"Kawakami J","year":"2014","unstructured":"Kawakami J. Visualization and analysis of drug information on adverse reactions using data mining method, and its clinical application. Yakugaku Zasshi. 2014, 134:105-18. 10.1248\/yakushi.13-00201","journal-title":"Yakugaku Zasshi"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5772\/50095","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi E","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, Ponti FD. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). Data Mining Applications in Engineering and Medicine. IntechOpen, Rijeka; 2012. 265-302. 10.5772\/50095"},{"key":"ref15","unstructured":"The Pharmaceuticals and Medical Devices Agency. The Japanese Adverse Drug Event Report (JADER) database. (2024). Accessed: July 2, 2024: https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0003.html."},{"key":"ref16","unstructured":"Food and Drug Administration. Guidance for industry E2B(R3). Electronic transmission of individual case safety reports (ICSRs) implementation guide. data elements and message specification. (2022). Accessed: July 2, 2024: http:\/\/www.fda.gov\/media\/81904\/download."},{"key":"ref17","unstructured":"Pharmaceutical and Medical Device Regulatory Science Society of Japan. Medical Dictionary for Regulatory Activities (MedDRA\/J). (2024). Accessed. July 2, 2024: https:\/\/www.jmo.pmrj.jp\/."},{"key":"ref18","unstructured":"The Japanese Society of Neuropsychopharmacology. Schizophrenia medication guide for patients and supporters 2022. (2022). Accessed. July 2, 2024: https:\/\/www.jsnp-org.jp\/csrinfo\/img\/szgl_guide_all2022.pdf."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20200051","article-title":"Contrasting typical and atypical antipsychotic drugs","volume":"19","author":"Meltzer HY","year":"2021","unstructured":"Meltzer HY, Gadaleta E. Contrasting typical and atypical antipsychotic drugs. Am Psychiatric Assoc. 2021, 19:3-13. 10.1176\/appi.focus.20200051","journal-title":"Am Psychiatric Assoc"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer HY","year":"2011","unstructured":"Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011, 11:59-67. 10.1016\/j.coph.2011.02.007","journal-title":"Curr Opin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects","volume":"2014","author":"Divac N","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014, 2014:656370. 10.1155\/2014\/656370","journal-title":"Biomed Res Int"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function","volume":"16","author":"Tarsy D","year":"2002","unstructured":"Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002, 16:23-45. 10.2165\/00023210-200216010-00003","journal-title":"CNS Drugs"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer HY","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003, 27:1159-72. 10.1016\/j.pnpbp.2003.09.010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref24","article-title":"Movement disorders associated with atypical antipsychotic drugs","volume":"63","author":"Caroff SN","year":"2002","unstructured":"Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002, 63:12-9.","journal-title":"J Clin Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2012-100850","article-title":"No difference in extrapyramidal side effects between first-generation and second-generation antipsychotics","volume":"15","author":"Carnahan R","year":"2012","unstructured":"Carnahan R. No difference in extrapyramidal side effects between first-generation and second-generation antipsychotics. Evid Based Ment Health. 2012, 15:91. 10.1136\/ebmental-2012-100850","journal-title":"Evid Based Ment Health"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso MJ","year":"2012","unstructured":"Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry. 2012, 200:387-92. 10.1192\/bjp.bp.111.101485","journal-title":"Br J Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108096901","article-title":"Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature","volume":"24","author":"Ahuja N","year":"2010","unstructured":"Ahuja N, Palanichamy N, Mackin P, Lloyd AJ. Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. J Psychopharmacol. 2010, 24:125-30. 10.1177\/0269881108096901","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2014.06.003","article-title":"Hyperosmolar hyperglycemic state secondary to neuroleptic malignant syndrome","volume":"33","author":"Takanobu K","year":"2015","unstructured":"Takanobu K, Okazaki D, Ogawa T, Watanabe S, Oka M, Murakami S, Ura H. Hyperosmolar hyperglycemic state secondary to neuroleptic malignant syndrome. Am J Emerg Med. 2015, 33:126.e1-2. 10.1016\/j.ajem.2014.06.003","journal-title":"Am J Emerg Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12597","article-title":"Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine","volume":"8","author":"Kaino K","year":"2017","unstructured":"Kaino K, Kumagai R, Furukawa S, et al.. Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine. J Diabetes Investig. 2017, 8:392-4. 10.1111\/jdi.12597","journal-title":"J Diabetes Investig"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12222","article-title":"Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome","volume":"130","author":"Su YP","year":"2014","unstructured":"Su YP, Chang CK, Hayes RD, et al.. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014, 130:52-60. 10.1111\/acps.12222","journal-title":"Acta Psychiatr Scand"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276387-evaluation-of-antipsychotic-induced-neuroleptic-malignant-syndrome-using-a-self-organizing-map","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T06:58:22Z","timestamp":1725087502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276387-evaluation-of-antipsychotic-induced-neuroleptic-malignant-syndrome-using-a-self-organizing-map"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.68260","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}